{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:20:44Z","timestamp":1789744844076,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteogenesis imperfecta (OI) is a heritable disease of connective tissue, characterized by increased bone fragility. Bisphosphonates currently seems to be the most promising therapy, at least in children. We tested IV neridronate, an amino-bisphosphonate structurally similar to alendronate and pamidronate in adults with OI. Twenty-three men and 23 premenopausal women with OI were randomized to either iv neridronate (100 mg infused intravenously for 30 minutes every 3 months) or no treatment with a ratio of 2 to 1. Control patients were given the same bisphosphonate therapy at the end of the first year. Clinical evaluation included bone densitometry measurements using dual energy X-ray absorptiometry (DXA), fasting serum and urinary biochemistry every 6 months, and radiographs of the spine taken at baseline and after 12 and 24 months of follow-up. Spine and hip bone mineral density rose by 3.0 \u00b1 4.6% (SD) and by 4.3 \u00b1 3.9%, respectively, within the first 12 months of treatment, whereas small insignificant changes were observed in the control group. During the second year of follow-up, additional 3.91% and 1.49% increases were observed at the spine and hip, respectively. Markers of skeletal turnover significantly fell during neridronate treatment. Fracture incidence during neridronate treatment was significantly lower than before therapy and compared with controls. Neridronate iv infusions, administered quarterly, significantly increase bone mineral density and lowered the risk of clinical fracture in adults with OI. Bisphosphonate therapy seems to provide clinical benefits, not only to children with OI, but also to adult patients.<\/jats:p>","DOI":"10.1359\/jbmr.2003.18.1.126","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T21:31:36Z","timestamp":1146087096000},"page":"126-130","source":"Crossref","is-referenced-by-count":128,"title":["Intravenous Neridronate in Adults With Osteogenesis Imperfecta"],"prefix":"10.1093","volume":"18","author":[{"given":"S","family":"Adami","sequence":"first","affiliation":[{"name":"Rheumatologic Rehabilitation, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Gatti","sequence":"additional","affiliation":[{"name":"Rheumatologic Rehabilitation, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Colapietro","sequence":"additional","affiliation":[{"name":"Rheumatologic Rehabilitation, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Fracassi","sequence":"additional","affiliation":[{"name":"Rheumatologic Rehabilitation, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Braga","sequence":"additional","affiliation":[{"name":"Rheumatologic Rehabilitation, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rossini","sequence":"additional","affiliation":[{"name":"Rheumatologic Rehabilitation, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Tat\u00f2","sequence":"additional","affiliation":[{"name":"Clinica Pediatrica, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019171818200_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0307-742X(21)00574-9","article-title":"Osteogenesis imperfecta","volume":"12","author":"Smith","year":"1986","journal-title":"Clin Rheum Dis"},{"key":"2024013019171818200_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"2024013019171818200_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00003086-197306000-00024","article-title":"New approaches to treatment of osteogenesis imperfecta","volume":"93","author":"Castells","year":"1973","journal-title":"Clin Orthop"},{"key":"2024013019171818200_bib4","first-page":"251","article-title":"The growth hormone and somatomedian axis in short children with osteogenesis imperfecta","volume":"76","author":"Marini","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019171818200_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","article-title":"Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta","volume":"97","author":"Horewitz","year":"2001","journal-title":"Blood"},{"key":"2024013019171818200_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skeletal Radiol"},{"key":"2024013019171818200_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-198801000-00017","article-title":"Is APD a promising drug in the treatment of severe osteogenesis imperfecta?","volume":"8","author":"Huaux","year":"1988","journal-title":"J Pediatr Orthop"},{"key":"2024013019171818200_bib8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton: Studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"2024013019171818200_bib9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0022-3476(97)70074-X","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"131","author":"Bembi","year":"1997","journal-title":"J Pediatr"},{"key":"2024013019171818200_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","article-title":"Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta","volume":"87","author":"\u00c5str\u00f6m","year":"1998","journal-title":"Acta Pediatr"},{"key":"2024013019171818200_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1515\/JPEM.2001.14.5.529","article-title":"Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta","volume":"14","author":"Gonzalez","year":"2001","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2024013019171818200_bib12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019171818200_bib13","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019171818200_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: Mechanism of action","volume":"19","author":"Fleisch","year":"2000","journal-title":"Endocrinol Rev"},{"issue":"Suppl 1","key":"2024013019171818200_bib15","first-page":"S35","article-title":"Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man","volume":"8","author":"McCloskey","year":"1987","journal-title":"Bone"},{"key":"2024013019171818200_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0002-9343(87)90699-1","article-title":"Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate","volume":"83","author":"Delmas","year":"1987","journal-title":"Am J Med"},{"key":"2024013019171818200_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jbmr.5650020403","article-title":"Aminohexane diphosphonate in the treatment of Paget, s disease of bone","volume":"2","author":"Atkins","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024013019171818200_bib18","first-page":"55","article-title":"Short-term intravenous therapy with neridronate in Paget's disease","volume":"220","author":"Adami","year":"2002","journal-title":"Clin Exper Rheumatol"},{"key":"2024013019171818200_bib19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019171818200_bib20","author":"WHO","year":"1994"},{"key":"2024013019171818200_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute-phase response after bisphosphonate administration","volume":"41","author":"Adami","year":"1987","journal-title":"Calcif Tissue Int"},{"key":"2024013019171818200_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates: A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Safety"},{"key":"2024013019171818200_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1203\/00006450-198303000-00007","article-title":"Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda","volume":"17","author":"Baron","year":"1983","journal-title":"Pediatr Res"},{"key":"2024013019171818200_bib24","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbmr.5650090706","article-title":"Bone resorption assessed by immunoassay of urinary cross linked collagen peptides in patients with osteogenesis imperfecta","volume":"9","author":"Brenner","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2024013019171818200_bib25","first-page":"S226","article-title":"Bone histomorphometric analysis in osteogenesis imperfecta","volume":"9","author":"Glorieux","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013019171818200_bib26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hockberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019171818200_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/jbmr.5650100402","article-title":"Assessment of involutional bone loss: Methodological and conceptual problems","volume":"10","author":"Adami","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013019171818200_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2024013019171818200_bib29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2003.18.1.126","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/18\/1\/126\/56473180\/5650180116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/18\/1\/126\/56473180\/5650180116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:05:42Z","timestamp":1710342342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/18\/1\/126-130\/7592645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2003,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.126","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,1,1]]},"published":{"date-parts":[[2003,1,1]]}}}